TEL : 02-792-1486 / FAX : 02-792-1410 / E-mail : cancer@kams.or.kr
Updated as of Feb-20, 2019
| 인사말 유희석 (대한암학회 회장) | 09:00-09:10 | |
| 1. | Dissecting tumor immune microenvironment | 09:10-10:40 |
| 좌장: 임종석 (숙명여대 이과대) | ||
| 1) | Impact of tumor-associated macrophages (TAM) in tumor hypoxia and aerobic glycolysis | |
| 안지완 (포항공대) | ||
| 2) | Reconstructing the tumor microenvironment using high dimensional single-cell analysis | |
| Michael Wong (MSD) | ||
| 3) | Understanding the biology of the TME using genomic analyses of tumor cells | |
| Steven M. Townson (MSD/Merck research Lab) | ||
| Coffee Break | 10:40-11:00 | |
| 2. | Strategies to overcome immune resistance | 11:00-12:30 |
| 좌장: 정현철 (연세의대) | ||
| 1) | Complex adaptive cancer immunotherapy | |
| 김인산 (한국과학기술연구원) | ||
| 2) | Myeloid-derived suppressor cells: A new therapeutic target to overcome resistance to checkpoint blockade therapy | |
| 연제인 (프로젠) | ||
| 3) | Oncolytic virus in cancer immunotherapy | |
| 라선영 (연세의대) | ||
| Luncheon Symposia | ||
| Luncheon Symposium 1 – Presented by Roche | 12:30-13:30 | |
| 좌장: 강진형 (가톨릭의대) | ||
| How immunotherapy is revolutionising 1L and 2L lung cancer care | ||
| 정현애 (성균관의대) | ||
| Luncheon Symposium 2 – Presented by ONO/BMS | 12:30-13:30 | |
| 좌장: 장대영 (한림의대) | ||
| Bringing clarity to clinical decisions in RCC and GC: Translating data into practice | ||
| 배우균 (전남의대) | ||
| 3. | Recent advances in cancer immunotherapy | 13:40-15:10 |
| 좌장: 박경화 (고려의대) | ||
| 1) | State of GBM immunotherapy | |
| Michael Lim (Johns Hopkins University School of Medicine) | ||
| 2) | Evidences of IO combination with standard of care: Lessons from breast cancer | |
| 박인혜 (국립암센터) | ||
| 3) | Genomics! Is immunotherapy right for me? | |
| 이대호 (울산의대) | ||
| Coffee Break | 15:10-15:30 | |
| 4. | Developmental therapeutics in immuno-oncology | 15:30-17:00 |
| 좌장: 강창율 (서울대 약대) | ||
| 1) | Enhancing cancer immunotherapy using biomaterials | |
| 박천권 (성균관대) | ||
| 2) | NK cell-based cancer immunotherapy for refractory cancer | |
| 최인표 (한국생명공학연구원) | ||
| 3) | Development of small molecule based immunotherapeutics for innovative anti-cancer treatment | |
| 이창훈 (한국화학연구원) | ||
| 4) | PharmAbcine and its immuno-oncology strategy | |
| 유진산 (파멥신) | ||